Archive for the ‘Uncategorized’ Category

Coldwater Creek Inc. (NASDAQ:CWTR) seems to be on its way down again. Yesterday, the stock soared approximately 42% on its price, and its volume exceeded 5 million shares. However, today the high trade was broken with no reasonable explanation.

Following the records, we can see that the recent price jump happened after Coldwater announced its improved financial results for the second quarter of this year. According to the report, the company has increased its revenue and gross profit, though it has incurred a net loss of approximately $5 million. This year, Coldwater opened five new premium retail stores, however, its cash decreased and the expenses totaled $169 million.

Though the losses, the company expects to gain future profit and projects earnings per share in the range of $0.01 to $0.04 for the third quarter of this year. Yesterday, Coldwater Creek was to host a conference call on its financial results, however there’s no further news on this issue yet.

Coldwater Creek Inc. is a national specialty retailer of women apparel, accessories, jewelry and gift items sold under the Coldwater Creek brand. Historically, the company used to trade about 50% higher, though since April, this year, the stock entered a downtrend. After the high trade yesterday, it is falling down again, so the only question now is what’s the next move of CWTR? It’s just up to be seen.

Yesterday, Law Offices of Howard G. Smith announced that it was investigating potential claims against the board of directors of Phoenix Technologies Ltd. (NASDAQ:PTEC). The investigation appears to be related to the agreement with the Marlin company, and the proposed cash totals approximately $139 million.

According to the press release, Marlin will acquire all outstanding shares of Phoenix common stock for $3.85 per share and the board of directors of Phoenix has already approved the cash transaction.

Looks like after reporting the news, the investors got interested in PTEC and the stock soared over 25% on its price. Along with the price jump, its traded volume exceeded the unusual 20 million shares. That’s a phenomenal value for Phoenix and it immediately placed it among the largest volume increases on NASDAQ.

But what’s going to happen after the big climb?

The latest financial results of PTEC show that its net income and gross profit are a bit lower as compared to the previous period and the company still has a net loss to cover. The good news for Phoenix is that it has more assets than liabilities on its balance sheet and no long-term debt.

Presently, the company is hopeful about its new agreement with Marlin and relies mainly on its financial resources. However, no one knows what’s to follow after the investigation of the Board is closed.

Yesterday, Icagen, Inc. (NASDAQ:ICGN) hit a huge volume gain. Just for a day, the stock sold over 774 thousand shares on the market and gained 8.22% on its price. That’s quite an unusual value for ICGN, as its average volume is only 125 shares traded.

What’s behind the stock’s high momentum then?

Apparently, that’s the news that ICGN won’t be delisted from NASDAQ at least by November, this year. According to Triangle Business Journal, “Nasdaq has granted the company’s request for more time to regain compliance with the $1.00 per share minimum bid price requirement”. Though, Icagen can not guarantee it will be able to reach the minimum price.

Still, last week, the company released another good news on receiving a $3 million milestone payment from Pfizer. Probably, that has impressed the investors, as currently, the stock still moves up.

Icagen, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of orally-administered small molecule drugs that modulate ion channel targets. Historical data shows that last year the company used to trade at over $1 per share, though after that the price fell down.

The ICGN’s first quarter results for this year point that its revenue and gross profit have increased, though it has suffered a net loss. According to the financial report, the company still has more assets than liabilities on its balance sheet, which should be sufficient to cover its current operations. However, ICGN stated that: “A substantial portion of our revenue for at least the next several years will depend on our achieving development and regulatory milestones in our existing collaborative research and development program and entering into new collaborations.”

Icagen claimed that it would need additional funds to meet its obligations and fund operations beyond the third quarter of 2010, and announced that its second quarter results are to be reported on 10 August.

After moving down to $1, Ampio Pharmaceuticals, Inc. (OTC:AMPE) started to climb up again. Yesterday, its price went up to $1.30 per share, and traded volume jumped up tremendously to exceed 2 thousand shares for the day.

What’s behing the present move? It should be the positive announcements along with the optimistic projections, released by AMPE over the last days. Could be these, that made the investors start buying, though the news is related to the future and the high expectations cannot be confirmed yet.

Ampio Pharmaceuticals develops innovative proprietary drugs for metabolic disease, eye disease, kidney disease, inflammation and CNS disease. According to the historical data, AMPE has traded much higher during the last 6 months, when its price reached $4.05 per share. However, there was a shocking price crash in June, this year. After that the stock has had frequent ups and downs to start moving up again. Still, its too soon an uptrend to be recorded.

The quarterly results of AMPE look disappointing. They point that the company has not generated any revenue so far, and it has suffered higher expenses. AMPE still has some cash on hand, though its operating loss has increased.

In its 2010 quarterly report, Ampio states that its: “Cash equivalents consist primarily of money market investments”, and that the company needs to raise additional capital to complete its business plan.

Based on these facts, traders should carefully observe the future movement of the AMPE stock.

Bayside Petroleum Company (BYSD.PK) sank down over 50% last week. After a resistance level at $0.030, the stock price ran down to $0.013 and its volume fell to 500 shares traded. Then, all of a sudden, the company’s traded volume ran up to over 3 million shares on Monday! This jump was phenomenal for the pink sheet company and it had no reasonable explanation.

The company has no recent press releases on its website and hasn’t made any general announcements during the last months. However, the records show that BYSD has paid 200k free trading shares to get promoted, which may explain the sudden volume jump.

The promoters can sell their shares right after the promotion, though in the BYSD case the price was probably artificially inflated. But still, we can find no definite explanation on the downtrend, which occurred. We can only assume the promoter has failed and decided to sell all the shares of BYSD.